Disease Landscape and Forecast Insights

Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s Kisunla (donanemab) have launched for the treatment of early Alzheimer’s disease (AD) in the United States and Japan and, after early…

Epilepsy is a complex neurological disorder marked by recurrent seizures, affecting approximately 4.7 million people across the major markets, as reported by Clarivate Epidemiology. Given epilepsy…

Myasthenia gravis (MG) is a rare autoimmune disorder in which antibodies impair acetylcholinemediated neuromuscular transmission, causing fluctuating muscle weakness. Generalized MG (gMG) often…

The mature Parkinson’s disease treatment market continues to evolve as newly launched pump therapies (i.e., AbbVie’s Vyalev, Supernus’s Onapgo), extended-release levodopa formulations (i.e.,…

Generalized onset seizures (GOS) originate simultaneously in both hemispheres of the brain and account for nearly 40% of all epilepsy cases. Current management relies primarily on widely used…

The market for multiple sclerosis (MS) disease-modifying therapies (DMTs) is crowded and competitive, as TG Therapeutics / Neuraxpharm’s Briumvi (ublituximab), Novartis’s Kesimpta (ofatumumab…

Amyotrophic lateral sclerosis (ALS) is a disorder of the central nervous system characterized by motor neuron degeneration. ALS causes progressive weakness and atrophy of the muscles and loss of…

Clarivate Epidemiology’s coverage of CIDP comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy,…

Clarivate Epidemiology’s coverage of diabetic neuropathy comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of diabetic…

Clarivate Epidemiology’s coverage of diabetic neuropathy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…

Clarivate Epidemiology’s coverage of diabetic neuropathy comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the total prevalence of diabetic…

Several new brands have recently entered the competitive Parkinson’s disease (PD) therapy market, including AbbVie’s Vyalev / Produodopa / Scyova (foslevodopa / foscarbidopa subcutaneous pump…